MannKind Corporation (NASDAQ:MNKD) will post its first quarter 2014 quarterly earnings on Monday May 12. Analysts estimate the company will post losses of 13 cents per share for the quarter. On average, analysts expect the company to post losses of 35 cents per share for the full fiscal year and losses of 20 cents per share for the next fiscal year. MannKind Corporation (NASDAQ:MNKD) weekly performance is -2.05%. On last trading day company shares ended up $6.22. Analysts mean target price for the company is $7.57. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average (SMA50) is 2.94%.
Gilead Sciences, Inc. (NASDAQ:GILD) announced results from a Phase 1 clinical trial of GS-6615, an investigational, selective late sodium current inhibitor, showing a shortening of the QTc interval in patients with long QT-3 syndrome.Gilead Sciences, Inc. (NASDAQ:GILD) shares advanced 1.31% in last trading session and ended the day on $79.76. GILD Gross Margin is 77.80% and its return on assets is 19.10%. Gilead Sciences, Inc. (NASDAQ:GILD) quarterly performance is 1.28%.
VIVUS, Inc. (Nasdaq:VVUS), or the Company, received notice from Actavis Laboratories FL, Inc. (NYSE: ACT), or Actavis, that it has filed with the U.S. Food and Drug Administration, or the FDA, an Abbreviated New Drug Application , or ANDA, for generic versions of all strengths of Qsymia (phentermine and topiramate extended release) capsules CIV. The notice from Actavis included a paragraph IV certification with respect to all of the Company’s patents listed in the FDA’s Orange Book on the date of the Company’s receipt of the notice. VIVUS, Inc. (NASDAQ:VVUS) shares moved down -2.79% in last trading session and was closed at $5.23, while trading in range of $5.08 – $5.44. VIVUS, Inc. (NASDAQ:VVUS) year to date (YTD) performance is -42.40%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that it will provide a corporate update and report first quarter 2014 financial results after the NASDAQ Global Select Market closes on Monday, May 12, 2014. That same day, Arena will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) ended the last trading day at $7.19. Company weekly volatility is calculated as 4.74% and price to cash ratio as 7.11. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) showed a positive weekly performance of 7.63%.
Leave a Reply